Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 6/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27634788 | 0.86 | NPC1 (0.84) | DYRK1AADORA1GAANPC1RAB9A | |
| SCHEMBL32674581 | 0.86 | NPC1 (0.84) | DYRK1AADORA1GAANPC1RAB9A | |
| SCHEMBL14942710 | 0.85 | ADORA1 (0.73) | DYRK1AADORA1GAACYP1A2NPC1 | |
| SCHEMBL12162704 | 0.85 | ADORA1 (0.73) | DYRK1AADORA1GAACYP1A2NPC1 | |
| SCHEMBL1580942 | 0.84 | NPC1 (0.73) | DYRK1AADORA1GAANPC1RAB9A | |
| SCHEMBL5211562 | 0.84 | ADORA1 (0.73) | DYRK1AADORA1GAANPC1RAB9A | |
| SCHEMBL3933070 | 0.84 | DYRK1A (0.72) | DYRK1AADORA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7090727 | 0.84 | ADORA1 (0.72) | DYRK1AADORA1GAACYP1A2NPC1 | |
| SCHEMBL133638 | 0.83 | ADORA1 (0.71) | DYRK1AADORA1GAACYP1A2NPC1 | |
| SCHEMBL8534896 | 0.83 | ADORA1 (0.71) | DYRK1AADORA1GAACYP1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3959200-A1 | NEW TRIAZOLE AND TRIAZOLOTHIADIAZINE DERIVATIVES EXERTING CYTOTOXIC AND APOPTOTIC EFFECTS ON A549 CELLS THROUGH AKT INHIBITION | Anadolu Universitesi (TR) | 2022-03-02 | — | — | EP | claimed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | claimed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | claimed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | claimed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| EP-0127133-B1 | PROCESS FOR THE PREPARATION OF 2-ACETYLAMINO-6-NITRO-BENZOTHIAZOLE AND 2-AMINO-6-NITRO-BENZOTHIAZOLE | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-03-16 | — | — | EP | claimed |
| US-4698297-A | INCLUDING A CHEMICALLY STABLE COMPOUND ABLE TO RELEASE A USEFUL CONTROLLABLE GROUP HAVING GOOD DIFFUSION; SHARPNESS | FUJI PHOTO FILM CO., LTD. (JP) | 1987-10-06 | — | — | US | claimed |
| US-4618571-A | STORAGE-STABLE COUPLERS; CONTROLLED-RELEASABLE COMPOUNDS | FUJI PHOTO FILM CO., LTD. (JP) | 1986-10-21 | — | — | US | claimed |
| US-4565777-A | Silver halide color photographic light-sensitive materials | FUJI PHOTO FILM CO., LTD. (JP) | 1986-01-21 | — | — | US | claimed |
| EP-0157146-A2 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1985-10-09 | — | — | EP | claimed |
| US-4526861-A | Heterocyclic ring contains imide or sulfonamide group | FUJI PHOTO FILM CO., LTD. (JP) | 1985-07-02 | — | — | US | claimed |
| US-4511649-A | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1985-04-16 | — | — | US | claimed |
| EP-0127133-A2 | Process for the preparation of 2-acetylamino-6-nitro-benzothiazole and 2-amino-6-nitro-benzothiazole | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-12-05 | — | — | EP | claimed |
| EP-0126433-A2 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1984-11-28 | — | — | EP | claimed |
| EP-0039835-A1 | Process for the preparation of 2-amino-6-nitro-benzothiazole | BAYER AG (DE) | 1981-11-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | DYRK1A 1004/4885ADORA1 33/4885GAA 3550/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | DYRK1A 1124/4885ADORA1 23/4885GAA 3357/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | DYRK1A 1004/4885ADORA1 33/4885GAA 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.